| Old Articles: <Older 47981-47990 Newer> |
|---|
 |
The Motley Fool
April 11, 2011 |
Transcript: Where Next for BP? A talk with Stanley Reed, the co-author of a new book on BP, In Too Deep.   |
The Motley Fool
April 11, 2011
Brian Orelli |
A Double Dose of Trouble for Big Pharma? Pfizer's Sutent and Novartis's Afinitor head in front of an FDA advisory panel. |
The Motley Fool
April 11, 2011
Anders Bylund |
This Just In: Even More Upgrades and Downgrades Analysts are piling on the hard-drive bandwagon by the truckload. |
The Motley Fool
April 11, 2011
Travis Hoium |
Energy Storage and the Future of Energy Batteries and compressed air will play a role in making renewable energies more effective. |
The Motley Fool
April 11, 2011
David Lee Smith |
Alcoa and Its Pals Gaining on Steel With the need to trim automotive weight, Alcoa and its pals just might benefit. |
The Motley Fool
April 11, 2011
Rich Smith |
Are U.S. Stocks Dirt Cheap? Europe seems to think so. |
The Motley Fool
April 11, 2011
Cindy Johnson |
Electronics for Imaging Shares Popped: What You Need to Know Electronics for Imaging popped 21% in intraday trading today after preliminary first-quarter results walloped expectations. |
The Motley Fool
April 11, 2011
Brian Orelli |
Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected. |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
The Motley Fool
April 11, 2011
Zeeshan Siddique |
Here's Why RBC Shouldn't Sell Its Retail U.S. Business Now Royal Bank of Canada shouldn't sell off its U.S retail unit as it may improve with the recovering economy. |
| <Older 47981-47990 Newer> Return to current articles. |
